You just read:

Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology

News provided by

Eli Lilly Canada Inc.

Jun 14, 2019, 15:24 ET